Omarigliptin Protects the Integrity of the Blood–Brain Barrier After Intracerebral Hemorrhage in Mice
Yan Zhang,Yang Liu,Xiangyu Zhang,V Wee Yong,Mengzhou Xue
DOI: https://doi.org/10.2147/jir.s411017
IF: 4.5
2023-06-15
Journal of Inflammation Research
Abstract:Yan Zhang, 1, 2 Yang Liu, 1, 2 Xiangyu Zhang, 1, 2 V Wee Yong, 3 Mengzhou Xue 1, 2 1 Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China; 2 Academy of Medical Science, Zhengzhou University, Zhengzhou, Henan, People's Republic of China; 3 Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada Correspondence: V Wee Yong, Hotchkiss Brain Institute and Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada, Email Mengzhou Xue, Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450001, People's Republic of China, Email Purpose: Intracerebral hemorrhage (ICH) is a fatal disease without effective treatment. The damage of the blood–brain barrier (BBB) is a key cause of brain edema and herniation after ICH. Omarigliptin (also known as MK3102) is a potent antidiabetic that inhibits dipeptidyl peptidase (DPP4); the latter has the ability to bind and degrade matrix metalloproteinases (MMPs). The present study aims to investigate the protective effects of omarigliptin against the destruction of BBB following ICH in mice. Methods and Materials: Collagenase VII was used to induce ICH in C57BL/6 mice. MK3102 (7 mg/kg/day) was administered after ICH. The modified neurological severity scores (mNSS) were carried out to assess neurological functions. Nissl staining was applied to evaluate neuronal loss. Brain water content, Evans blue extravasation, Western blots, immunohistochemistry and immunofluorescence were used to study the protective effects of BBB with MK3102 at 3 days after ICH. Results: MK3102 reduced DPP4 expression and decreased hematoma formation and neurobehavioral deficits of ICH mice. This was correspondent with lowered activation of microglia/macrophages and infiltration of neutrophils after ICH. Importantly, MK3102 protected the integrity of the BBB after ICH, associated with decreased expression of MMP-9, and preservation of the tight junction proteins ZO-1 and Occludin on endothelial cells through putative degradation of MMP-9, and inhibition of the expression of CX43 on astrocytes. Conclusion: Omarigliptin protects the integrity of the BBB in mice after ICH injury. Keywords: intracerebral hemorrhage, dipeptidyl peptidase, blood–brain barrier, omarigliptin Intracerebral hemorrhage (ICH) is an intractable health burden with 17.9 million sufferers globally. 1 Although great progress has been gained due to the development of surgery for hematoma evacuation in recent years, the prognosis of ICH is far from satisfactory. The mortality rate of ICH remains as high as 68%. 1 Perihematomal edema caused by the disruption of the blood–brain barrier (BBB) is closely associated with poor outcomes after ICH. 2–5 With every milliliter increase in brain edema, the chances of malfunctioning doubles, especially for the occurrence of herniation. 6 The BBB is mainly composed of the extracellular matrix (ECM), endothelial cells, astrocytes, and the cellular junctions (tight junction, eg, zonula occludens, ZOs; gap junction, eg, connexins, CXs; and adherence junction) between them. 7 Preclinical evidence has informed that the BBB in ICH is damaged due to the reduction of those cellular junctions (collagenase IV/VII and autologous blood injection). 8 In addition, matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases that proteolyze ECM members, are significantly increased after ICH and cause BBB breakdown by directly degrading junctional proteins. 7,9 Therefore, targeted maintenance of BBB integrity to reduce brain edema and secondary brain injury has been an appealing therapeutic strategy for the treatment of ICH. 10 Dipeptidyl peptidase 4 (DPP4) is a membrane-associated peptidase encoded by mitochondria and widely distributed in body organs to exert pleiotropic effects via degrading target peptide, such as glucagon-like peptide-1 (GLP-1), GIP, and neuropeptide Y. 11 Recent evidence suggests that DPP4 has the ability to degrade ECM by binding to ECM directly or binding to adenosine deaminase and activating MMPs. 12 Among all MMPs, the activity of MMP9 and MMP1 was most affected by DPP4. 13 Moreover, DPP4 also mediates MMP activation and Cx43 internalization by stimulating the mitogen-activated protein kinase (MAPK) pathway. 14,15 In addition, MMPs expression and ECM degradation can be regulated by GLP-1. 16 These collective evidence suggest that DPP4 may be a pote -Abstract Truncated-
immunology